Medtech seeking to reduce the mental burden associated with diabetes thanks to interoperable self-learning solutions⚡
Medtech seeking to reduce the mental burden associated with diabetes thanks to interoperable self-learning solutions⚡
Sector: Medtech — automated insulin delivery (therapeutic AI)
Founded: 2015 (Grenoble, France)
Employees: 125
Total funding: €132,300,000
Core products: DBLG1 (marketed) and DBLG2 (next-generation automated insulin delivery)
Type 1 diabetes management — automated/personalized insulin delivery using AI
2015
Medical devices / Digital health
Most recent announced round (11 investors listed in sources)
“Backed by a mix of strategic and financial investors including Terumo (strategic), LBO France (growth/private equity), UI Investissement, Innovacom, Kreaxi, Supernova Invest, Odyssée Venture, Crédit Agricole and CERITD”